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Abstract 
Purpose: To investigate the effects of the Chinese compound, Songyu Anshen Fang (SYF) on levels of 
GABA and GABA(B) receptor proteins in insomniac rats induced by para-chlorophenylalanine (PCPA). 
Methods: All rats were randomly separated into either a control group, insomnia group, or a SYF group 
(at a dose of 8.5 g/kg or 17 g/kg body weight per day). The rat model of insomnia was induced by 
intraperitoneal injection of PCPA, and SYF was administered intragastrically in suspension. All 
experimental groups were treated with a corresponding agent for one week. The levels of glutamic acid 
(Glu) and γ-aminobutyric acid (GABA) were determined by high performance liquid chromatography 
(HPLC); mRNA and protein expressions, and GABA(B) receptor levels were detected by real-time 
polymerase chain reaction (RT-PCR) and western blot. 
Results: SYF treatment with 8.5 or 17 g/kg/day decreased the levels of Glu and Glu/GABA ratios in the 
hypothalamus following abnormal increase by PCPA. Moreover, GABA(B) receptor, mRNA and protein 
expression decreased by PCPA in hypothalamus were significantly normalized by SYF. 
Conclusion: The study indicates that the effects of PCPA-induced insomnia can be alleviated by SYF 
modulation of neurotransmitter levels and the expression of GABA(B) receptor in the hypothalamus. 
This suggests that clinical application of SYF to treat insomnia may be feasible. 
 
Keywords: Songyu Anshen Fang, Para-chlorophenylalanine (PCPA), γ-Aminobutyric acid (GABA), 
GABA(B) receptor, Insomnia 
 
This is an Open Access article that uses a funding model which does not charge readers or their institutions 
for access and distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Insomnia is a widespread health problem and 
increasing incidence of insomnia, due to an 
accelerated life pace, renders insomnia research 
extremely important. Insomnia is attributed at 
least in part to the role of neurotransmitters in 
regulation of sleep and wakefulness. These 
neurotransmitters include histaminergic, nor-
adrenergic, and cholinergic neurotransmission 
[1,2]. GABA is the major inhibitory 
neurotransmitter and plays an important role in 
-----------------------------------------------------------------------------------------------------------------------------------------------------
© 2018  The authors. This work is licensed under the Creative Commons Attribution 4.0 International License 
 
 
Zeng et al 
Trop J Pharm Res, January 2018; 17(1):18 
 
the regulation of sleep [3]. Monoaminergic 
mechanisms have been reportedly involved in 
sleep regulation in various mammals [4-6]. 
Administration of para-chlorophenylalanine 
(PCPA), a specific inhibitor of serotonin (5-HT) 
synthesis, decreases the level of 5-HT in several 
species of mammals, leading to reduced sleep 
[7-10]. Therefore, in this study, we developed a 
rat model of insomnia based through the 
administration of PCPA. 
 
The Chinese compound Songyu Anshen Fang 
(SYF) exhibits significant clinical therapeutic 
effects on insomnia. Previous pharmacological 
studies have additionally shown that SYF can 
improve cognitive disorders in insomniac rats via 
the modulation of neurotransmitters 5-HT and DA 
[11]. There is also evidence that GABA and 
GABA(B) receptors are involved in the 
occurrence and development of insomnia. 
However, the underlying mechanism of SYF’s 
therapeutic effect on insomnia remains unclear. 
In this study we investigated the effects of SYF 
on levels of glutamic acid, γ-aminobutyric acid 







Adult male Sprague-Dawley rats (weighing 230 – 
280 g, Shanghai Slaccas Animal Center, 
Shanghai, China) were selected for these 
experiments. All the rats were housed 
individually at a temperature of 22 oC and a 
humidity of 50 % under controlled illumination 
(12:12 h dark:light cycle; light on at 06:00 hours). 
At all times, rats had free access to food and 
water. The experimental procedures described 
herein were approved by the Animal Care 
Committees at the Fujian Academy of Traditional 
Chinese Medicine (no. FJATCM-IAEC 2016003) 
and the study followed the Guide for the 
Assessment and Accreditation of Laboratory 
Animal Care International (AAALAC) for 




DL-p-chlorophenylalanine hydrochloride (PCPA, 
Sigma) was dissolved in saline with a pH 
adjusted to 7.2. The insomnia model was 
established by injection of 300 mg/kg PCPA 
intraperitoneally (i.p.) at 19:00 h for two 
consecutive days. The rats in the control group 
received 0.9 % saline in place of PCPA. Rats in 
the Songyu Anshen Fang (SYF) group were 
administered a suspension of SYF (8.5 and 17 
g/kg per day) intragastrically at 8:00 h for 7 
consecutive days. Rats in the model group and 
control group received equal amounts of sterile 
water. Two hours after the last day of SYF 
administration, the animals were deeply 
anesthetized by intraperitoneal injection of 
pentobarbital sodium (65 mg/kg) and the 
hypothalamus was excised and flash frozen in 
liquid nitrogen, followed by storage at −80 °C. 
 
Measurement of excitatory amino acids 
 
The levels of GABA and glutamate were 
detected by high performance liquid 
chromatography. Seventy (70 µL) of AccQ∙Tag 
Fluor borate buffer and 20 µL of AccQ∙Tag 
derivative reagent were added to 10 µL of 
sample or standard solution followed by 
vortexing. The mixture was allowed to react for 
10 min at 55 oC. The derivatized sample (10 µL) 
was then injected onto a C18 reversed phase 
column. A Waters HPLC-FLD (model: 2475) 
fitted with a Waters AccQ∙Tag column (150 
mm × 3.9 mm, 4 µm) was set to an excitation 
wavelength (Ex) = 250 nm, emission wavelength 
(Em) = 395 nm, and column temperature of 40 
oC. The mobile phase was comprised of 0.1 M 
sodium acetate buffer (pH 6.8, A) 
and acetonitrile (B). The flow rate was set to 1.0 
ml/min. All solvents were filtered by vacuum 
through a 0.22 µm membrane (Millipore) and 
degassed by sonication for 30 min before use. 
 
Quantitative real-time PCR 
 
Total RNA was extracted by the RNAprep pure 
tissue kit (Tiangen). Contaminating DNA was 
removed by DNase (Tiangen) treatment. The 
absorbance of the product was detected at 260 
and 280 nm by a spectrophotometer to 
determine the concentration and purity, 
respectively. Total RNA was reverse-transcribed 
into cDNA using the Quantscript First strand 
Synthesis system (Tiangen). cDNA amplification 
was performed by 7500 fast Sequence Detection 
System (Applied Biosystems, Foster, CA, USA) 
and SYBR Premix Ex Taq (Takara). The PCR 
conditions were: 95 °C for 30 s, followed by 40 
cycles at 95 °C for 5 s, at 60 °C for 30 s. All 
samples were examined in triplicates. Primer 
Express software was used to design primer 
sequences, the results of which are presented in 
Table 1. 
 
Table 1: Primer sequences for real-time PCR 
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Western blot was used to assess GABA(B) 
proteins in the hypothalamus quantitatively. 
Frozen specimens were homogenized in 300 µL 
of RIPA buffer containing 50 mM Tris-HCL (pH 
7.4), 150 mM NaCl, 1 % NP-40, 0.1 % sodium 
dodecyl sulfate (SDS), and 1 mM PMSF. 
Following centrifugation (13,100 g for 10 min, 4 
°C), the supernatant was used to estimate the 
total amount of protein. Samples with equal 
amounts of protein were loaded onto a 8 % 
SDS–polyacrylamide gel for electrophoresis  
 
Proteins were transferred to a PVDF membrane. 
After blocking of nonspecific binding sites with T-
TBS containing 3 % bovine serum albumin (2 h 
at room temperature), membranes were 
incubated with the primary antibody rabbit anti-
GABA(B)1 (1:200; Santa Cruz) at 4 °C overnight. 
Next, the membrane was incubated with 
secondary antibody, HRP-conjugated goat anti-
rabbit IgG (1:5000; Abcam), for 1 h. After rinsing 
with a buffer, the immuno-complexes were 
visualized by chemiluminescence using the ECL 
kit (Thermo). Protein expression in the 
hypothalamus was determined by measuring the 
optical density using an image analysis system 




Experimental data are displayed as mean ± 
SEM. Data were processed with SPSS l7.0 
statistical analysis software. Statistical 
significance between groups was examined by 
one-way analysis of variance (ANOVA) followed 
by Tukey’s test for multiple comparisons.  P < 




Effect of SYF on levels of Glu and GABA in 
the hypothalamus of rats 
 
To observe the effects of SYF on levels of Glu 
and GABA in the hypothalamus of insomniac 
rats, the levels of Glu and GABA were 
determined by HPLC. The regression equation 
correlation coefficient of the determined amino 
acids is shown in Table 2 and the representative 
chromatograms of Glu and GABA are presented 
in Figure 1 A and B. Results showed that after 
PCPA treatment, the levels of Glu in 
hypothalamus were remarkably increased (p < 
0.001), and Glu/GABA ratios increased 
significantly (p < 0.05) compared with the saline 
group. However, the levels of Glu were 
significantly decreased (p < 0.01, p < 0.001) in 
response to varying doses of SYF for 7 days. 
Glu/GABA ratios were also significantly reduced 
(p < 0.01, p < 0.001) by SYF treatment when 
compared with the PCPA group (Figure 2) 
 
Table 2: Regression equation and correlation 
coefficient of the determined amino acids 
 
Amino acid Regression equation R 
Glu Y = 1.92e + 008X + 4.11e+ 
005 
0.9999 






Figure 1: Representative chromatograms of Glu and 
GABA. A is chromatogram of amino acid solution 
standards; B is chromatogram of the hypothalamus of 
insomniac rats 
 
Effect of SYF on mRNA expression of 
GABA(B) 
 
RT-PCR results showed that after PCPA 
treatment, GABA(B) mRNA expression was 
significantly decreased (p < 0.001) in rat 
hypothalamus compared with the saline control 
group. However, GABA(B) mRNA expression in 
rat hypothalamus was significantly increased (p < 
0.05, p < 0.001) in response to SYF intervention 
when compared with the PCPA group (Figure 3). 
 
Effects of SYF on GABA(B) protein 
expression  
 
Western blot analysis showed that after PCPA 
treatment, GABA(B) was significantly decreased 
(p < 0.001) in rat hypothalamus when compared 
with saline control group. On the other hand, 
GABA(B) expression in rat hypothalamus was 
significantly increased (p < 0.05, p < 0.001) after 
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administration of SYF when compared with 
PCPA group (Figure 4). 
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Figure 2: Effect of SYF on Levels of Glu and 
GABA in the rat hypothalamus; ***p < 0.001, * p 
< 0.05 vs Saline group; ###p < 0.001, ##p < 0.01 








































Figure 3: Effect of SYF on the expression level of 
GABA(B) mRNA in the hypothalamus of insomnia rats 
induced by PCPA; ***p < 0.001 vs Saline group ; ###p 

































Figure 4: Effect of SYF on the level of GABA(B) in the 
hypothalamus of insomnia rats induced by PCPA; ***p 





As a specific and irreversible inhibitor of the 
aromatic amino acid hydroxylase tryptophan 5-
monooxygenase, PCPA is the rate-limiting 
enzyme of serotonin (5HT) biosynthesis [7]. 
Application of PCPA significantly reduces the 
concentration of 5-HT across several species of 
mammals, a phenomenon accompanied by a 
reduction in sleep [7-10]. 
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Brain regions that are involved in the sleep 
process include the brainstem, hypothalamus, 
basal forebrain, pontine reticular formation, and 
locus coeruleus. These structures form the 
activation-induction system of sleep and receive 
fiber projections from serotonin-releasing nerves 
in the dorsal raphe nucleus. Many inhibitory 
neurotransmitters exist in the sleep-related 
hypothalamic region [13]. Damage of these brain 
regions or alterations of the balance of neuronal 
transmission between the major excitatory 
neurotransmitter (Glu) and the inhibitory 
substance (GABA) can directly affect the sleep 
architecture [14].Therefore, we chose the 
hypothalamus as a detection area and GABA 
and Glu as indicators in our assessment of 
changes in sleeping patterns in response to 
PCPA-induced insomnia and SYF intervention. 
 
GABA is the major inhibitory neurotransmitter 
and has a key role in modulating neuronal 
activity. GABA acts through ionotropic (GABAA R 
and GABAC R) and metabotropic (GABAB R) 
receptors, which produce slow and fast inhibitory 
signals, respectively. As a heterodimer, GABAB 
R1 and GABAB R2 play an important role in the 
fine-tuning of inhibitory synaptic transmissions 
which have been implicated in muscle relaxation, 
hippocampal long-term potentiation, slow wave 
sleep and antinociceptive events.  
 
SYF is a Chinese herbal formula that contains 
Gansong (the radix of Nardostachys chinensis 
Batal), Yujin (the tuberous root of Curcuma 
petiolata), Meiguihua (the flower of Rosa 
rugosa), Shenglonggu (Fossilia Ossis Mastodi), 
Zhenzhumu (the powder of Concha Margaritifera 
Usta), Yejiaoteng (Cauls Polugoni Multiflori), 
Danshen (the radix of Salviae Miltiorrhizae), 
Suanzaoren (the kernel of Semen Ziziphi 
Spinosae), and Hehuanpi (the skin of Cortex 
Albiziae). This study investigated the effect of 
SYF on the expression of hypothalamic GABA 
and GABA(B) receptor proteins in PCPA-induced 
insomnia in rats. In the present study, SYF 
treatment with 8.5 or 17 g/kg/day significantly 
normalized the expression of GABA(B) mRNA 
and GABA(B) protein in the hypothalamus of 
PCPA-treated rats. The results indicate that the 
effect of SYF on PCPA-treated rats might be 
associated with the modulation of 
neurotransmitter levels and the GABA(B) 




The findings of this study demonstrate that 
PCPA-induced insomnia is alleviated in rats by 
SYFs. The mechanism may be related to the 
modulation of neurotransmitter levels and the 
expression of GABA(B) receptor in the 
hypothalamus by SYF. Thus, SYF has potentials 
for clinical application in the treatment of 
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